Home | Publications | Diabetes and Obesity

Diabetes and Obesity

Discover the papers published by Diabesity – Diabetes and Obesity Working Group.

10 / 11 results found

FINE-ONE, more to come: moving beyond ACEis and ARBs in type 1 diabetes with kidney disease?

June 15, 2026

Diabesity WG

Obesity as a modifiable risk factor in patients with chronic kidney disease

October 30, 2025

Diabesity WG

How to individualise renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA

May 13, 2025

Diabesity WG

The future of glucagon-like peptide-1 receptor agonists in cardiovascular–kidney–metabolic diseases considerations from the ERA Diabesity Working Group

January 11, 2025

Diabesity WG

SELECT: a 10% reduction in body weight with GLP-1 receptor agonists improves kidney outcomes in overweight and obese patients without diabetes

September 20, 2024

Diabesity WG

Diabesity CME 2022

September 16, 2022

Diabesity WG

The Role of Vascular Lesions in Diabetes Across a Spectrum of Clinical Kidney Disease

June 11, 2021

Diabesity WG

Underlying Mechanisms of Renal Lipotoxicity in Obesity

September 20, 2019

Diabesity WG

Do Endocannabinoids Regulate Glucose Reabsorption in the Kidney?

September 20, 2019

Diabesity WG

Beta Cell Functional Adaptation and Dysfunction in Insulin Resistance and the Role of Chronic Kidney Disease

September 20, 2019

Diabesity WG

Join the ERA Working Groups or renew your interest

Discover our Members’ stories

Enjoy the exclusive access to all webcasts of #ERA26 until September 7, 2026

YNP Mentorship: Experiences of Mentors and Mentees

Explore the Neph-Manual

Try the Beetroot dumplings

New e-seminar summary report

ERA Registry Annual Report 2023

Suggestions

Diabetes and Obesity

{%TITLE%}

{%TITLE%}

FINE-ONE, more to come: moving beyond ACEis and ARBs in type 1 diabetes with kidney disease?

Obesity as a modifiable risk factor in patients with chronic kidney disease

How to individualise renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA

The future of glucagon-like peptide-1 receptor agonists in cardiovascular–kidney–metabolic diseases considerations from the ERA Diabesity Working Group

SELECT: a 10% reduction in body weight with GLP-1 receptor agonists improves kidney outcomes in overweight and obese patients without diabetes

Diabesity CME 2022

The Role of Vascular Lesions in Diabetes Across a Spectrum of Clinical Kidney Disease

Underlying Mechanisms of Renal Lipotoxicity in Obesity

Do Endocannabinoids Regulate Glucose Reabsorption in the Kidney?

Beta Cell Functional Adaptation and Dysfunction in Insulin Resistance and the Role of Chronic Kidney Disease